IMMUNE-MEDIATED FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)

Clinical trials for IMMUNE-MEDIATED FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) explained in plain language.

Never miss a new study

Get alerted when new IMMUNE-MEDIATED FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) trials appear

Sign up with your email to follow new studies for IMMUNE-MEDIATED FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug trial seeks to calm overactive immune system

Disease control Recruiting now

This is a first-in-human study to check if a new injectable drug called VIS171 is safe for people with certain autoimmune diseases like lupus, alopecia areata, or a kidney disease called FSGS. About 30 participants will receive the drug along with their standard care for up to a …

Matched conditions: IMMUNE-MEDIATED FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)

Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control

Last updated Mar 25, 2026 14:08 UTC

IMMUNE-MEDIATED FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)

Get alerted when new IMMUNE-MEDIATED FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) trials appear

New drug trial seeks to calm overactive immune system